Clinical Trial Update: NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

This Phase 1 trial update reports termination of NUV-868 as monotherapy and in combination with olaparib or enzalutamide in adults with advanced solid tumors, i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Pancreatic Cancer
• Prostate Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Lynparza (olaparib)
• NUV-868
• Xtandi (enzalutamide)

Snippet

Sponsor: Nuvation Bio Inc. | Conditions: Advanced Solid Tumor, Ovarian Cancer | Phase 1 | Status: TERMINATED